Ischemic Cardiomyopathy Clinical Trial
— AGENT-HFOfficial title:
Phase 2 Study of SERCA2a Gene Transfer in Patients With Severe Heart Failure
Verified date | August 2017 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the effect of intracoronary SERCA2a Gene transfer on cardiac volumes and function using multimodality cardiac imaging.
Status | Terminated |
Enrollment | 10 |
Est. completion date | February 2016 |
Est. primary completion date | September 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Patients with NYHA class III / IV severe heart failure = 3 months - Ischemic or non-ischemic origin - Left ventricular ejection fraction =35% - Patients must be receiving optimal (maximum tolerated doses) medical treatment (diuretics, renin-angiotensin-aldosterone system blockers, beta blockers, ±Ivabradine) for at least 1 month (with the exception of diuretic dose titration) and must be stable. - No decompensated congestive heart failure within the past month - With or without an ICD if the ICD was implanted over 3 months ago, with or without biventricular pacing if the RCT was implanted over 6 months ago - All women of childbearing potential must have a negative urine pregnancy test prior to administration of investigational medicinal product - Patient must have given written informed consent to participate in this study Exclusion Criteria: - <18 or >80 years old - AAV1 seropositivity (titer <1:2) in the last 3 months - Atrial fibrillation in the absence of permanent ventricular pacing - Coronary revascularization or heart surgery or pacemaker implantation < 3 months - Ischemic heart disease without at least one coronary artery with a TIMI-3 flow - Restrictive cardiomyopathy, hypertrophic obstructive cardiomyopathy, pericardial disease, cardiac amyloidosis - Heart transplant, an already implanted or needing to urgently implant external ventricular assist device - Myocardial infarction (STEMI or NSTEMI) < 3 months - Treatment with intravenous positive inotropic agents or diuretics in the past 28 days - Pregnant or nursing patient - Female patient of childbearing age with no effective means of contraception - Severe renal failure defined by a creatinine clearance of < 30 mL/min (last bloodwork done less than 6 months) - Liver failure, chronic liver disease or laboratory tests > 3 x N (AST, ALT, ALP))(last bloodwork done less than 6 months) - Thrombocytopenia (<50,000/mm3 - Patient treated with immunosuppressants, has an immunodeficiency or whose neutrophil count < 1000 mm3 - Recent sepsis (< 3 months) - Active neoplasia or treated < 5 years - No medical insurance - Patient is enrolled in another randomized study - Patient does not understand the protocol procedures sponsor suspects poor compliance with the protocol |
Country | Name | City | State |
---|---|---|---|
France | CHU Pitié-Salpêtrière | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris | Celladon Corporation |
France,
Hulot JS, Salem JE, Redheuil A, Collet JP, Varnous S, Jourdain P, Logeart D, Gandjbakhch E, Bernard C, Hatem SN, Isnard R, Cluzel P, Le Feuvre C, Leprince P, Hammoudi N, Lemoine FM, Klatzmann D, Vicaut E, Komajda M, Montalescot G, Lompré AM, Hajjar RJ; AG — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | left ventricular end-systolic volume measured by CT-Scan | left ventricular end-systolic volume measured by CT-Scan / changes from baseline to 6 months | at 6 months | |
Secondary | CT-scan other measurments: left ventricular end-diastolic volume | CT-scan other measurments: left ventricular end-diastolic volume / changes from baseline to 6 and 12 months | at 6 and 12 months | |
Secondary | Cardiac volumes and function | Cardiac volumes and function / changes from baseline to 6 months & 12 months | at 6 and 12 months | |
Secondary | Cardiac hemodynamic parameters | Cardiac hemodynamic parameters; changes from baseline to 6 months | at 6 months | |
Secondary | VO2 max | VO2 max; changes from baseline to 6 months and 12 months | at 6 and 12 months | |
Secondary | Cardiac function assessed by echocardiography | Changes from baseline to 6 and12 months in:Echocardiographic assessments | at 6 and12 months | |
Secondary | Quality of Life (Kansas city score) | Changes from baseline to 3,6,9,12 months in:Quality of Life | at 3,6,9,12 months | |
Secondary | NT-ProBNP | Changes from baseline to 6 and12 months in:NT-ProBNP | at 6 and12 months | |
Secondary | Time to cardiovascular event | Time to cardiovascular event (all-cause death, heart transplant, LVAD implantation) - administration to 12 months | at 6 and 12 months | |
Secondary | Number of hospitalized patients for worsening heart failure | at 6 and 12 months | ||
Secondary | Cardiac volumes assessed by echocardiography | Changes from baseline to 6 and12 months in:Echocardiographic assessments | at 6 and12 months | |
Secondary | CT-scan other measurments: left ventricular end-systolic volume | CT-scan other measurments: left ventricular end-systolic volume / changes from baseline to 12 months | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04066738 -
Scar Location and Acute Haemodynamic Response to MultiPoint Pacing Study in Patients With Ischemic Cardiomyopathy
|
N/A | |
Recruiting |
NCT03536052 -
Ablation at Virtual-hEart pRedicted Targets for VT
|
N/A | |
Enrolling by invitation |
NCT02930265 -
Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy
|
N/A | |
Completed |
NCT01215253 -
Ranolazine Implantable Cardioverter-Defibrillator Trial
|
Phase 3 | |
Completed |
NCT04508608 -
Scintigraphic Evaluation of Contractile and Coronary Reserve in Patients With Ischemic Cardiomyopathy
|
||
Recruiting |
NCT05888662 -
Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy (EPIC-VT)
|
N/A | |
Completed |
NCT03857906 -
Evaluation of Prophylactic Use of a Preoperative IABP in High-Risk Coronary Artery Bypass Graft Surgery
|
||
Completed |
NCT02501811 -
Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure
|
Phase 2 | |
Recruiting |
NCT02058771 -
Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
|
||
Not yet recruiting |
NCT01946048 -
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic Cardiomyopathy
|
Phase 1 | |
Terminated |
NCT01759212 -
Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure.
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT01447069 -
Use of Beta-agonists in Stable Severe Congestive Heart Failure
|
N/A | |
Recruiting |
NCT00972114 -
CABG Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Ischemic Cardiomyopathy
|
Phase 1/Phase 2 | |
Completed |
NCT00896142 -
Optima Coronary Artery Disease (CAD) (Optimal Mechanical Evaluation)
|
N/A | |
Recruiting |
NCT01076660 -
Left Ventricular Structural Predictors of Sudden Cardiac Death
|
||
Completed |
NCT00305240 -
MASTER I - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients
|
N/A | |
Completed |
NCT00305214 -
MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients
|
N/A | |
Active, not recruiting |
NCT00962364 -
Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease
|
||
Recruiting |
NCT05769036 -
Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients
|
N/A | |
Completed |
NCT03862339 -
The SoundScar Study The SOUNDSCAR Study
|